Carphenazine

CHEMBL1201328 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

425.6 g/mol

LogP

3.1

Phase

4

A phenothiazine-class antipsychotic historically used in the treatment of schizophrenia and other psychotic disorders. It shares the dopamine-blocking mechanism of other typical antipsychotics in this class. It is now largely obsolete, having been replaced by newer agents with improved side effect profiles.

Molecular Weight

425.6000 g/mol

LogP

3.10

TPSA

72.30 Å²

Lipinski RO5

Pass

Mechanism of Action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2

InChI

InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3

Molecular Formula

C24H31N3O2S

HBD / HBA

1 / 6

Rotatable Bonds

8

Heavy Atoms

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A phenothiazine-class antipsychotic historically used in the treatment of schizophrenia and other psychotic disorders. It shares the dopamine-blocking mechanism of other typical antipsychotics in this class. It is now largely obsolete, having been replaced by newer agents with improved side effect profiles.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Carphenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201328. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 18104. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Carphenazine on PillFYI

Structure

Quick Data

Formula: C24H31N3O2S

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.